STOCK TITAN
  1. Home
  2. News
  3. TLSA

Tiziana Life Sciences Ltd. Common Shares - TLSA STOCK NEWS

Welcome to our dedicated page for Tiziana Life Sciences Ltd. Common Shares news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Ltd. Common Shares stock.

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a progressive clinical-stage biotechnology company committed to developing transformative therapies targeting neurodegenerative and lung diseases. The company leverages innovative drug-delivery technologies to create novel treatments aimed at improving patient outcomes.

Key to Tiziana's portfolio are two prominent compounds: Milciclib and Foralumab. Milciclib, an inhibitor of cyclin-dependent kinases, is in Phase II clinical trials for thymic carcinoma, aiming to provide new hope for patients who have exhausted chemotherapy options. Foralumab, noted for being the only fully human-engineered anti-CD3 monoclonal antibody, is in various stages of clinical development for multiple sclerosis, autoimmune, and inflammatory diseases.

In a significant advancement, Tiziana recently reported positive clinical outcomes from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS). Intranasal administration of Foralumab led to remarkable improvement in fatigue symptoms in 70% of patients over six months, as measured by the Modified Fatigue Impact Scale (MFIS). These results signify a groundbreaking step in addressing an unmet need in MS treatment.

The company's commitment to innovation is backed by strategic partnerships with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital. Tiziana’s leadership team brings extensive experience in drug development and commercialization, ensuring a firm trajectory toward regulatory approvals and market entry.

Moreover, Tiziana’s pipeline includes potential therapies for conditions like ALS, Alzheimer's, and Crohn's Disease, underscoring its dedication to tackling a broad spectrum of debilitating conditions. The company’s forward-looking approach aims to revolutionize treatment paradigms through enhanced drug delivery systems that promise increased efficacy and reduced side effects.

With a robust clinical pipeline, strategic collaborations, and innovative technologies, Tiziana Life Sciences Ltd. remains at the forefront of biopharmaceutical research, poised to make significant strides in the field of immunomodulation therapies.

News

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Rhea-AI Summary
Tiziana Life Sciences (TLSA) announces an upcoming oral presentation on the treatment of PIRA with Nasal Foralumab for Multiple Sclerosis at the AAN Annual Meeting. Presenter is Tarun Singhal from Harvard Medical School. The presentation aims to dampen microglial activation and stabilize clinical progression in Non-Active Secondary Progressive MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
-
News

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

Rhea-AI Summary
Tiziana Life Sciences Ltd. presents positive data on intranasal anti-CD3 monoclonal antibody for Alzheimer’s and Parkinson’s disease at AD/PD conference. The data shows reduction in microglia activation and improvement in behavior in rodent models. Nasal anti-CD3 also reduces hemorrhage and edema associated with ARIA. Neuroinflammation modulation may enhance approved treatments for Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none
-
News

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced positive findings in a study of patients with na-SPMS, showing improvements in fatigue scores and reduction in microglial activation. The Company is developing breakthrough neuro-immunomodulation therapies and has seen promising results in the Expanded Access (EA) patients. The study is being led by prominent figures in the medical field and has potential implications for the ongoing Phase 2 clinical trial of intranasal foralumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
News

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, on January 8-10, 2024. The presentation will focus on the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
News

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced the filing of a new patent application for combining GLP-1ra and foralumab to reduce systemic and vascular inflammation associated with Type 2 Diabetes and non T2D obesity. The application describes the potential for foralumab to provide additional risk reduction for major adverse cardiovascular events. The company aims to provide a new therapeutic option for patients receiving GLP-1 receptor antagonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
News

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the dosing of the first patient in its Phase 2a study for intranasal foralumab in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The trial aims to compare two doses of foralumab and placebo, with a primary endpoint of change in microglial activation based on PET scans. The study also includes assessments of clinical parameters and immuno-biomarkers. The company hopes to provide a new therapeutic option for na-SPMS patients, as there are currently no FDA-approved treatments for this condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
clinical trial
News

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on December 6th at 3:00 PM ET. The presentation will focus on recent clinical updates and Phase 2 trial of intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
-
News

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Program. A total of ten patients are now being followed in the EA Program, marking a critical step forward in Tiziana Life Sciences' mission to provide treatment options for patients living with this debilitating disease while collecting valuable regulatory evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
News

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Rhea-AI Summary
Tiziana Life Sciences (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, will present at BIO-Europe in Munich, Germany. The presentation will focus on the clinical updates of intranasal foralumab for the treatment of diseases like multiple sclerosis and Alzheimer's. The company's management will also participate in one-on-one partnering meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Rhea-AI Summary
Tiziana Life Sciences receives FDA approval for multiple sclerosis patients to self-administer Intranasal Foralumab at home
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none

FAQ

What is the current stock price of Tiziana Life Sciences Ltd. Common Shares (TLSA)?

The current stock price of Tiziana Life Sciences Ltd. Common Shares (TLSA) is $0.9522 as of November 22, 2024.

What is the market cap of Tiziana Life Sciences Ltd. Common Shares (TLSA)?

The market cap of Tiziana Life Sciences Ltd. Common Shares (TLSA) is approximately 99.7M.

What is Tiziana Life Sciences Ltd. specialized in?

Tiziana Life Sciences Ltd. specializes in developing transformative therapies for neurodegenerative and lung diseases using innovative drug-delivery technologies.

What are the key compounds in Tiziana's pipeline?

The key compounds in Tiziana's pipeline are Milciclib, an inhibitor of cyclin-dependent kinases, and Foralumab, the only fully human-engineered anti-CD3 monoclonal antibody.

What recent clinical results has Tiziana announced?

Tiziana announced positive results from its Expanded Access Program for non-active secondary progressive multiple sclerosis (na-SPMS), where 70% of patients showed improvement in fatigue symptoms after six months of treatment with intranasal Foralumab.

Who are Tiziana Life Sciences' key partners?

Tiziana partners with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital to advance its clinical research and development.

What diseases are targeted by Foralumab?

Foralumab targets multiple sclerosis, autoimmune diseases like ulcerative colitis, and inflammatory diseases such as Crohn's Disease and type-1 diabetes.

What is unique about Tiziana’s drug delivery approach?

Tiziana uses a nasal delivery method for Foralumab, which has demonstrated enhanced efficacy, safety, and tolerability compared to traditional intravenous delivery.

What is the status of Milciclib's clinical development?

Milciclib is currently in Phase II clinical trials for thymic carcinoma, aiming to provide a new treatment option for patients who have previously undergone chemotherapy.

Who leads Tiziana Life Sciences?

Tiziana is led by a team of experienced executives, including Chairman and acting CEO Gabriele Cerrone, who have extensive backgrounds in drug development and commercialization.

What is the significance of Tiziana's Expanded Access Program?

The Expanded Access Program allows patients with non-active secondary progressive multiple sclerosis (na-SPMS) to receive treatment with Foralumab, showing significant improvements in fatigue and stability in disease progression.

How does Tiziana Life Sciences contribute to biopharmaceutical research?

Tiziana is at the forefront of biopharmaceutical research, developing new therapies and drug delivery systems to address unmet needs in neurodegenerative and autoimmune diseases.

Stock TLSA logo
Tiziana Life Sciences Ltd. Common Shares

Nasdaq:TLSA

TLSA Rankings

#4375 Ranked by Market Cap
N/A Ranked by Dividends

TLSA Stock Data

99.67M
71.31M
35.56%
0.94%
0.23%
Biotechnology
Healthcare
Link
United States of America
London